Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2015, Article ID 948159, 11 pages
http://dx.doi.org/10.1155/2015/948159
Review Article

Medication Exposures and Subsequent Development of Ewing Sarcoma: A Review of FDA Adverse Event Reports

1Office of Pediatric Therapeutics, Office of Special Medical Programs, Office of the Commissioner/Food and Drug Administration, Building 32, Room 5156, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA
2Office of Hematology and Oncology Products, OND, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, White Oak Bldg. 22, Room 2202, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA
3U.S. Public Health Service Commissioned Corps, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, White Oak Bldg. 22, Room 3410, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA

Received 10 January 2015; Revised 6 March 2015; Accepted 26 April 2015

Academic Editor: Cyril Fisher

Copyright © 2015 Judith U. Cope et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Judith U. Cope, Gregory H. Reaman, and Joseph M. Tonning, “Medication Exposures and Subsequent Development of Ewing Sarcoma: A Review of FDA Adverse Event Reports,” Sarcoma, vol. 2015, Article ID 948159, 11 pages, 2015. https://doi.org/10.1155/2015/948159.